FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders

• Published in: Pharmaceuticals (Basel, Switzerland) Switzerland), 2022-12, Vol.15 (12), p.1546
• Main Authors: Lui, Austin, Vanleuven, Jordan, Perekopskiy, David, Liu, Dewey, Xu, Desiree, Alzayat, Omar, Elgokhy, Taiseer, Do, Timothy, Gann, Meghan, Martin, Ryan, Liu, Da-Zhi
• Format: Article
• Language: English
• Subjects: aberrant cell cycle disease; Alzheimer's disease; Amyotrophic lateral sclerosis; Cancer therapies; cancers; Drug therapy; kinase inhibitors; Kinases; Nervous system diseases; Neurological disorders; Review; Traumatic brain injury
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph15121546

Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed "Aberrant Cell Cycle Diseases" (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer's disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments.